Document Type
Article
Publication Date
6-1-2016
Abstract
It was hypothesized that the four-factor prothrombin complex concentrate (4F-PCC) Kcentra 25 unit/kg would reverse impairment of thrombin generation in healthy volunteers dosed with apixaban to steady state. In this randomized, two-period crossover, assessor-blinded trial, 12 healthy subjects received 5 mg apixaban every 12 h. Three h after the fifth dose, four-factor prothrombin complex concentrate (4F-PCC) 25 unit/kg or saline were infused. Serial blood samples were assessed for thrombin generation using PPP-reagent and PPP-reagent low, anti-Xa, PT, and PTT assays. Geometric mean ratio was calculated at 30 min postinfusion, and at 24, 48, and 72 h. Peak thrombin generation was 76% higher at 30 min postinfusion with 4F-PCC (p = 0.025). The difference declined to 24% at 24 h and resolved by 48 h. Other thrombin generation parameters were also partially normalized. There was no difference between 4F-PCC and saline in anti-Xa assessment at 30 min or later time points.
Recommended Citation
Nagalla, S; Thomson, Lynda; Oppong, Y; Bachman, B; I Chervoneva; and Kraft, walter k., "Reversibility of Apixaban Anticoagulation with a Four-Factor Prothrombin Complex Concentrate in Healthy Volunteers." (2016). Department of Pharmacology and Experimental Therapeutics Faculty Papers. Paper 68.
https://jdc.jefferson.edu/petfp/68
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
PubMed ID
27170068
Comments
This article has been peer reviewed. It was published in: Clinical and Translational Science.
Volume 9, Issue 3, 1 June 2016, Pages 176-180.
The published version is available at DOI: 10.1111/cts.12398
Copyright © 2016 The Authors